AQST (STOCKS)
Aquestive Therapeutics, Inc. Common Stock
$4.303900
+0.073900 (+1.75%)
Prev close: $4.230000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel Barber
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $593.25M
- Employees
- 142
- P/E (TTM)
- -6.51
- P/B (TTM)
- -9.38
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
10
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.18 | $-0.11 | -0.0746 | -70.78% |
|
Mar 2026 (Q1)
|
$-0.07 | $-0.14 | +0.0699 | +49.96% |
|
Dec 2025 (Q4)
|
$-0.15 | $-0.14 | -0.0148 | -10.95% |
|
Sep 2025 (Q3)
|
$-0.14 | $-0.14 | -0.0048 | -3.55% |
Financial Statements
| Revenues | $54.09M |
| Benefits Costs and Expenses | $132.31M |
| Cost Of Revenue | $17.83M |
| Costs And Expenses | $106.83M |
| Gross Profit | $36.26M |
| Operating Expenses | $89.00M |
| Selling, General, and Administrative Expenses | $73.11M |
| Depreciation and Amortization | $518.00K |
| Research and Development | $15.89M |
| Operating Income/Loss | -$52.75M |
| Income/Loss From Continuing Operations After Tax | -$78.23M |
| Income/Loss From Continuing Operations Before Tax | -$78.23M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$78.23M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$78.23M |
| Net Income/Loss Available To Common Stockholders, Basic | -$78.23M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.66 |
| Diluted Earnings Per Share | -$0.66 |
| Basic Average Shares | 363,257,085 |
| Diluted Average Shares | 363,257,085 |
| Assets | $132.10M |
| Current Assets | $118.49M |
| Accounts Receivable | $9.33M |
| Inventory | $7.37M |
| Other Current Assets | $101.80M |
| Noncurrent Assets | $13.61M |
| Fixed Assets | $3.96M |
| Other Non-current Assets | $9.65M |
| Liabilities | $188.69M |
| Current Liabilities | $16.48M |
| Accounts Payable | $8.97M |
| Wages | $3.22M |
| Other Current Liabilities | $4.29M |
| Noncurrent Liabilities | $172.21M |
| Long-term Debt | $55.00M |
| Other Non-current Liabilities | $117.21M |
| Equity | -$56.59M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$56.59M |
| Liabilities And Equity | $132.10M |
| Net Cash Flow From Operating Activities | -$45.37M |
| Net Cash Flow From Operating Activities, Continuing | -$45.37M |
| Net Cash Flow From Investing Activities | -$584.00K |
| Net Cash Flow From Investing Activities, Continuing | -$584.00K |
| Net Cash Flow From Financing Activities | $83.90M |
| Net Cash Flow From Financing Activities, Continuing | $83.90M |
| Net Cash Flow | $37.95M |
| Net Cash Flow, Continuing | $37.95M |
| Comprehensive Income/Loss | -$78.23M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$78.23M |
| Other Comprehensive Income/Loss | -$70.17M |